SCHEMBL4710893

SCHEMBL4710893

COc1ccc(C)nc1C=Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP1B1 Q16678 2/20 0.53
TRPA1 O75762 2/20 0.50
NFE2L2 Q16236 2/20 0.50
TUBB1 Q9H4B7 2/20 0.49
GRM4 Q14833 4/20 0.49
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 2/20 0.49
HPGD P15428 2/20 0.49
NPC1 O15118 1/20 0.49
GRM5 P41594 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
MEN1 O00255 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4710891 1.00 CYP1A1 (0.53) CYP1A1CYP1A2CYP1B1TRPA1NFE2L2
SCHEMBL4713415 0.82 RELA (0.52) CYP1A1CYP1A2CYP1B1NFE2L2SMN1; SMN2
SCHEMBL4713419 0.82 RELA (0.52) CYP1A1CYP1A2CYP1B1NFE2L2SMN1; SMN2
SCHEMBL18150002 0.81 GRM4 (0.44) CYP1A1CYP1A2CYP1B1TRPA1NFE2L2
SCHEMBL18150005 0.81 GRM4 (0.44) CYP1A1CYP1A2CYP1B1TRPA1NFE2L2
SCHEMBL6381048 0.80 L3MBTL1 (0.45) GRM4ALDH1A1KDM4EHPGDNPC1
SCHEMBL6381052 0.80 L3MBTL1 (0.45) GRM4ALDH1A1KDM4EHPGDNPC1
SCHEMBL4711138 0.80 AHR (0.49) CYP1A1CYP1B1TUBB1KDM4ERAB9A
SCHEMBL4711139 0.80 AHR (0.49) CYP1A1CYP1B1TUBB1KDM4ERAB9A
SCHEMBL3900932 0.78 SRC (0.53) PDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP claimed
EP-0998459-A2 PYRIDINE DERIVATIVES Novartis AG (CH) 2000-05-10 EP claimed
WO-1999002497-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 1999-01-21 WO claimed
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed